vs
Forestar Group Inc.（FOR）与Guardant Health, Inc.（GH）财务数据对比。点击上方公司名可切换其他公司
Guardant Health, Inc.的季度营收约是Forestar Group Inc.的1.0倍（$281.3M vs $273.0M），Forestar Group Inc.净利率更高（5.6% vs -45.7%，领先51.3%），Guardant Health, Inc.同比增速更快（39.4% vs 9.0%），Guardant Health, Inc.自由现金流更多（$-54.2M vs $-157.1M），过去两年Guardant Health, Inc.的营收复合增速更高（29.2% vs -9.6%）
福雷斯特集团是一家住宅地块开发企业，总部位于得克萨斯州阿灵顿，业务覆盖美国21个州的51个市场。截至2020年12月31日的12个月内，该公司交付了11518块住宅地块，目前在纽约证券交易所上市，自2002年起就是美国规模最大的住宅建筑商D.R. Horton的控股子公司。
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
FOR vs GH — 直观对比
营收规模更大
GH
是对方的1.0倍
$273.0M
营收增速更快
GH
高出30.3%
9.0%
净利率更高
FOR
高出51.3%
-45.7%
自由现金流更多
GH
多$102.9M
$-157.1M
两年增速更快
GH
近两年复合增速
-9.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $273.0M | $281.3M |
| 净利润 | $15.4M | $-128.5M |
| 毛利率 | 20.1% | 64.6% |
| 营业利润率 | 7.6% | -43.0% |
| 净利率 | 5.6% | -45.7% |
| 营收同比 | 9.0% | 39.4% |
| 净利润同比 | -6.7% | -15.8% |
| 每股收益（稀释后） | $0.30 | $-1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FORGH
| Q4 25 | $273.0M | $281.3M | ||
| Q3 25 | $670.5M | $265.2M | ||
| Q2 25 | $390.5M | $232.1M | ||
| Q1 25 | $351.0M | $203.5M | ||
| Q4 24 | $250.4M | $201.8M | ||
| Q3 24 | $551.3M | $191.5M | ||
| Q2 24 | $318.4M | $177.2M | ||
| Q1 24 | $333.8M | $168.5M |
净利润FORGH
| Q4 25 | $15.4M | $-128.5M | ||
| Q3 25 | $86.9M | $-92.7M | ||
| Q2 25 | $32.9M | $-99.9M | ||
| Q1 25 | $31.6M | $-95.2M | ||
| Q4 24 | $16.5M | $-111.0M | ||
| Q3 24 | $81.5M | $-107.8M | ||
| Q2 24 | $38.7M | $-102.6M | ||
| Q1 24 | $45.0M | $-115.0M |
毛利率FORGH
| Q4 25 | 20.1% | 64.6% | ||
| Q3 25 | 22.3% | 64.7% | ||
| Q2 25 | 20.4% | 65.0% | ||
| Q1 25 | 22.6% | 63.3% | ||
| Q4 24 | 22.0% | 61.6% | ||
| Q3 24 | 23.9% | 61.1% | ||
| Q2 24 | 22.5% | 59.1% | ||
| Q1 24 | 24.9% | 61.2% |
营业利润率FORGH
| Q4 25 | 7.6% | -43.0% | ||
| Q3 25 | 16.9% | -37.3% | ||
| Q2 25 | 11.2% | -45.9% | ||
| Q1 25 | 11.6% | -54.6% | ||
| Q4 24 | 8.7% | -62.4% | ||
| Q3 24 | 19.7% | -61.3% | ||
| Q2 24 | 16.2% | -56.8% | ||
| Q1 24 | 17.6% | -59.2% |
净利率FORGH
| Q4 25 | 5.6% | -45.7% | ||
| Q3 25 | 13.0% | -35.0% | ||
| Q2 25 | 8.4% | -43.0% | ||
| Q1 25 | 9.0% | -46.8% | ||
| Q4 24 | 6.6% | -55.0% | ||
| Q3 24 | 14.8% | -56.3% | ||
| Q2 24 | 12.2% | -57.9% | ||
| Q1 24 | 13.5% | -68.2% |
每股收益（稀释后）FORGH
| Q4 25 | $0.30 | $-1.01 | ||
| Q3 25 | $1.70 | $-0.74 | ||
| Q2 25 | $0.65 | $-0.80 | ||
| Q1 25 | $0.62 | $-0.77 | ||
| Q4 24 | $0.32 | $-0.90 | ||
| Q3 24 | $1.59 | $-0.88 | ||
| Q2 24 | $0.76 | $-0.84 | ||
| Q1 24 | $0.89 | $-0.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $211.7M | $378.2M |
| 总债务越低越好 | $793.2M | $1.5B |
| 股东权益账面价值 | $1.8B | $-99.3M |
| 总资产 | $3.2B | $2.0B |
| 负债/权益比越低杠杆越低 | 0.44× | — |
8季度趋势，按日历期对齐
现金及短期投资FORGH
| Q4 25 | $211.7M | $378.2M | ||
| Q3 25 | $379.2M | $580.0M | ||
| Q2 25 | $189.2M | $629.1M | ||
| Q1 25 | $174.3M | $698.6M | ||
| Q4 24 | $132.0M | $525.5M | ||
| Q3 24 | $481.2M | $585.0M | ||
| Q2 24 | $359.2M | $933.7M | ||
| Q1 24 | $416.2M | $1.0B |
总债务FORGH
| Q4 25 | $793.2M | $1.5B | ||
| Q3 25 | $802.7M | $1.1B | ||
| Q2 25 | $872.8M | $1.1B | ||
| Q1 25 | $872.5M | $1.1B | ||
| Q4 24 | $806.8M | $1.1B | ||
| Q3 24 | $706.4M | — | ||
| Q2 24 | $706.1M | — | ||
| Q1 24 | $705.7M | — |
股东权益FORGH
| Q4 25 | $1.8B | $-99.3M | ||
| Q3 25 | $1.8B | $-354.5M | ||
| Q2 25 | $1.7B | $-305.5M | ||
| Q1 25 | $1.6B | $-250.8M | ||
| Q4 24 | $1.6B | $-139.6M | ||
| Q3 24 | $1.6B | $-60.1M | ||
| Q2 24 | $1.5B | $-1.6M | ||
| Q1 24 | $1.5B | $68.3M |
总资产FORGH
| Q4 25 | $3.2B | $2.0B | ||
| Q3 25 | $3.1B | $1.3B | ||
| Q2 25 | $3.1B | $1.3B | ||
| Q1 25 | $3.0B | $1.3B | ||
| Q4 24 | $3.0B | $1.5B | ||
| Q3 24 | $2.8B | $1.5B | ||
| Q2 24 | $2.7B | $1.6B | ||
| Q1 24 | $2.6B | $1.7B |
负债/权益比FORGH
| Q4 25 | 0.44× | — | ||
| Q3 25 | 0.45× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.53× | — | ||
| Q4 24 | 0.50× | — | ||
| Q3 24 | 0.44× | — | ||
| Q2 24 | 0.47× | — | ||
| Q1 24 | 0.48× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-157.0M | $-26.4M |
| 自由现金流经营现金流 - 资本支出 | $-157.1M | $-54.2M |
| 自由现金流率自由现金流/营收 | -57.5% | -19.3% |
| 资本支出强度资本支出/营收 | 0.0% | 9.9% |
| 现金转化率经营现金流/净利润 | -10.19× | — |
| 过去12个月自由现金流最近4个季度 | $93.0M | $-233.1M |
8季度趋势，按日历期对齐
经营现金流FORGH
| Q4 25 | $-157.0M | $-26.4M | ||
| Q3 25 | $256.3M | $-35.4M | ||
| Q2 25 | $15.8M | $-60.3M | ||
| Q1 25 | $-19.8M | $-62.7M | ||
| Q4 24 | $-450.0M | $-64.5M | ||
| Q3 24 | $119.2M | $-51.1M | ||
| Q2 24 | $-61.7M | $-94.0M | ||
| Q1 24 | $-59.2M | $-30.3M |
自由现金流FORGH
| Q4 25 | $-157.1M | $-54.2M | ||
| Q3 25 | $255.6M | $-45.8M | ||
| Q2 25 | $15.0M | $-65.9M | ||
| Q1 25 | $-20.5M | $-67.1M | ||
| Q4 24 | — | $-83.4M | ||
| Q3 24 | $118.4M | $-55.3M | ||
| Q2 24 | $-62.3M | $-99.1M | ||
| Q1 24 | $-59.8M | $-37.2M |
自由现金流率FORGH
| Q4 25 | -57.5% | -19.3% | ||
| Q3 25 | 38.1% | -17.3% | ||
| Q2 25 | 3.8% | -28.4% | ||
| Q1 25 | -5.8% | -33.0% | ||
| Q4 24 | — | -41.3% | ||
| Q3 24 | 21.5% | -28.9% | ||
| Q2 24 | -19.6% | -55.9% | ||
| Q1 24 | -17.9% | -22.1% |
资本支出强度FORGH
| Q4 25 | 0.0% | 9.9% | ||
| Q3 25 | 0.1% | 3.9% | ||
| Q2 25 | 0.2% | 2.4% | ||
| Q1 25 | 0.2% | 2.2% | ||
| Q4 24 | 0.0% | 9.4% | ||
| Q3 24 | 0.1% | 2.2% | ||
| Q2 24 | 0.2% | 2.9% | ||
| Q1 24 | 0.2% | 4.1% |
现金转化率FORGH
| Q4 25 | -10.19× | — | ||
| Q3 25 | 2.95× | — | ||
| Q2 25 | 0.48× | — | ||
| Q1 25 | -0.63× | — | ||
| Q4 24 | -27.27× | — | ||
| Q3 24 | 1.46× | — | ||
| Q2 24 | -1.59× | — | ||
| Q1 24 | -1.32× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FOR
| D.R.Horton Inc. | $183.8M | 67% |
| Other | $89.2M | 33% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
